Skip to main content
S. 4109 119th Congress Senate

Stem Cell Therapeutic and Research Reauthorization Act of 2026

Official title: A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

Introduced: March 17, 2026 Introduced by: Jack Reed Democratic · Rhode Island See on congress.gov
Health Biological and life sciencesBlood and blood diseasesCell biology and embryologyHealth programs administration and fundingOrgan and tissue donation and transplantation
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 22, 2026
Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.
Jun 22, 2026
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
Jun 17, 2026
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Mar 17, 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1093)
Mar 17, 2026
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now June 22, 2026

Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.

 Plain-English summary Congressional Research Service

Stem Cell Therapeutic and Research Reauthorization Act of 2026

This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).

The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. The bill also expands periodic reviews of the state of stem cell science to specifically include a review of the use of high-quality cord blood units and other emergent technologies to develop new therapies for potential inclusion in the program.

Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

 Hearings & markups 1
 Related & companion bills 1
  • HR 5160 Stem Cell Therapeutic and Research Reauthorization Act of 2025
 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 18

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 18 filings →
 Cosponsors 3
All 3 Democratic 1 Republican 2
R
Lankford, James
Oklahoma · Mar 17, 2026
 R
Scott, Tim
South Carolina · Mar 17, 2026
 D
Smith, Tina
Minnesota · Mar 17, 2026
Cite this page click to expand
APA
U.S. Congress. (2026). S. 4109: Stem Cell Therapeutic and Research Reauthorization Act of 2026. 119th Congress. Open America. https://openamerica.io/bill/119-S-4109/
MLA
"S. 4109: Stem Cell Therapeutic and Research Reauthorization Act of 2026." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-4109/.
Bluebook (legal)
S. 4109, 119th Cong. (2026), https://openamerica.io/bill/119-S-4109/.
Markdown link
[S. 4109: Stem Cell Therapeutic and Research Reauthorization Act of 2026](https://openamerica.io/bill/119-S-4109/)
Report a problem